

Seth Baum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7756715/publications.pdf>

Version: 2024-02-01

57
papers

3,616
citations

361045
20
h-index

174990
52
g-index

60
all docs

60
docs citations

60
times ranked

3969
citing authors

#	ARTICLE	IF	CITATIONS
1	Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. <i>European Heart Journal</i> , 2022, 43, 1401-1412.	1.0	78
2	Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). <i>Nature Medicine</i> , 2022, 28, 96-103.	15.2	128
3	Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2022, 16, 617-625.	0.6	15
4	Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. <i>Future Cardiology</i> , 2021, 17, 155-174.	0.5	14
5	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 264-275.	5.5	109
6	Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100177.	1.3	11
7	Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. <i>American Journal of Preventive Cardiology</i> , 2021, 8, 100278.	1.3	14
8	Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2020, 382, 244-255.	13.9	559
9	Cardiovascular disease prevention in the health economics era: Clinicians need more than just prescription pads. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100004.	1.3	0
10	Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to <i>ANGPTL3</i> mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. <i>European Heart Journal</i> , 2020, 41, 3936-3945.	1.0	188
11	Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100009.	1.3	90
12	Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005404.	0.9	59
13	Rounding the corner on residual risk: Implications of REDUCE ω 3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease. <i>Clinical Cardiology</i> , 2019, 42, 829-838.	0.7	13
14	Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 901-909.e3.	0.6	14
15	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1926-1942.	1.2	39
16	Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1780.	3.8	314
17	Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2019, 394, 2012-2024.	6.3	401
18	Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data. <i>The Lancet Digital Health</i> , 2019, 1, e393-e402.	5.9	49

#	ARTICLE	IF	CITATIONS
19	<p>Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified</p>. Therapeutics and Clinical Risk Management, 2019, Volume 15, 1325-1332.	0.9	4
20	PCSK9 inhibitor valuation: A scienceâ€based review of the two recent models. Clinical Cardiology, 2018, 41, 544-550.	0.7	7
21	The 2017 high blood pressure clinical practice guideline: The old and the new. Clinical Cardiology, 2018, 41, 279-281.	0.7	2
22	Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY) Tj ETQq0 0 0 rgBT/Overlook 10 Tf 50	1.7	10
23	Clinical Genetic Testing for Familialâ€Hypercholesterolemia. Journal of the American College of Cardiology, 2018, 72, 662-680.	1.2	387
24	The American Society for Preventive Cardiology. Clinical Cardiology, 2018, 41, 709-709.	0.7	1
25	Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study. Journal of Clinical Lipidology, 2018, 12, 1234-1243.e5.	0.6	40
26	Access to PCSK9 Inhibitors. Reviews in Cardiovascular Medicine, 2018, 19, 47-50.	0.5	0
27	Familial Hypercholesterolemia: Although Identification Advances, Appreciation and Treatment Lag. Reviews in Cardiovascular Medicine, 2018, 19, 25-30.	0.5	0
28	A review of the evidence for alternative and complementary medical approaches in the prevention of atherosclerotic cardiovascular disease and diabetes. Cardiovascular Endocrinology, 2017, 6, 39-43.	0.8	2
29	Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease. Circulation, 2017, 135, 2204-2206.	1.6	34
30	CHARACTERISTICS OF PATIENTS APPROVED AND DENIED ACCESS TO PCSK9I THERAPY BY PAYERS. Journal of the American College of Cardiology, 2017, 69, 2534.	1.2	2
31	<scp>PCSK9</scp> inhibitor access barriersâ€issues and recommendations: Improving the access process for patients, clinicians and payers. Clinical Cardiology, 2017, 40, 243-254.	0.7	71
32	Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FHâ„ patient registry. Atherosclerosis, 2017, 267, 19-26.	0.4	64
33	The 2017 American Society for Preventive Cardiology Congress and Experts Course. Clinical Cardiology, 2017, 40, 520-520.	0.7	0
34	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 58.	0.4	16
35	US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. Journal of Clinical Lipidology, 2016, 10, 1223-1229.	0.6	57
36	Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice. Postgraduate Medicine, 2016, 128, 31-39.	0.9	4

#	ARTICLE	IF	CITATIONS
37	The American Society for Preventive Cardiology: Our 30-year legacy. <i>Clinical Cardiology</i> , 2016, 39, 627-630.	0.7	4
38	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 850-861.	5.5	329
39	Accelerated atherosclerosis and elevated lipoprotein (a) after liver transplantation. <i>Journal of Clinical Lipidology</i> , 2016, 10, 434-437.	0.6	3
40	Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 240-249.	5.1	170
41	Statins and Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, 87-100.	1.2	12
42	Rethinking our Guideline System: Returning to Evidence Based Medicine as it was Originally Intended. <i>Journal of Hypertension and Management</i> , 2016, 2, .	0.1	0
43	Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia. <i>Reviews in Cardiovascular Medicine</i> , 2016, 17, 16-27.	0.5	2
44	Dissecting lipid and lipoprotein issues in women: an in utero-through-menopause journey. <i>Clinical Lipidology</i> , 2015, 10, 431-448.	0.4	0
45	Diagnosing Familial Hypercholesterolemia (FH) in the United States: Results from the CASCADE FH Patient Registry. <i>Journal of Clinical Lipidology</i> , 2015, 9, 451-452.	0.6	0
46	Statins and Diabetes. <i>Cardiology Clinics</i> , 2015, 33, 233-243.	0.9	14
47	The doctor's dilemma: Challenges in the diagnosis and care of homozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2014, 8, 542-549.	0.6	17
48	From the "Ivory Tower" to the trenches: A practical approach to the 2013 ACC/AHA Cholesterol and Risk Assessment Guidelines. <i>Journal of Clinical Lipidology</i> , 2014, 8, 231-233.	0.6	1
49	ANCHOR Trial Conclusions Regarding the Effects of Pure Eicosapentaenoic Acid on Low-Density Lipoprotein Cholesterol. <i>American Journal of Cardiology</i> , 2013, 111, 454-455.	0.7	6
50	A Survey of Internists and Cardiologists: Are Discoveries in Fatty Acids Truly being translated into Clinical Practice?. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2013, 88, 3-4.	1.0	5
51	Pitfalls of Population-Based Preventive Medicine. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2201.	3.8	2
52	EPA and DHA: Distinct yet essential n-3 fatty acids. <i>Journal of Clinical Lipidology</i> , 2012, 6, 477.	0.6	2
53	Fatty acids in cardiovascular health and disease: A comprehensive update. <i>Journal of Clinical Lipidology</i> , 2012, 6, 216-234.	0.6	201
54	Evidence-Based Medicine: What's the Evidence?. <i>Clinical Cardiology</i> , 2012, 35, 259-260.	0.7	3

#	ARTICLE	IF	CITATIONS
55	Fatty Acids and Their Derivatives in Cardiovascular Disease: Arachidonic, Eicosapentaenoic, and Docosahexaenoic Acids and Their Byproducts, the Eicosanoids and Docosanoids. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 146-154.	0.8	5
56	MR Imaging in the Definition of Coronary Artery Anomalies. <i>Journal of Computer Assisted Tomography</i> , 1990, 14, 171-174.	0.5	17
57	Acute Reversible Diffuse Conduction System Disease due to Lyme Disease. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1990, 13, 1367-1370.	0.5	6